• News&Topics
  • 2023.04.27

    At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of Nanvuranlat (development code: JPH203) will be announced. Nanvuranlat is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients.

COPYRIGHT ©
J PHARMA.CO.,LTD
ALL RIGHTS RESERVED